A recent feature from CBS News examined whether Johnson & Johnson and Bayer, the makers of Xarelto, knowingly withheld certain important data for a letter to be published in the New England Journal of Medicine. The specific claim made by lawyers for Xarelto plaintiffs in the multi-district litigation (MDL) class action…
According to a recent news feature from the New York Times, the United States Food and Drug Administration (FDA) is now conducting an investigation into whether a blood testing device used during clinical trials, which we now know to be defective, led to an approval of Xarelto that never should…
Xarelto, Eliquis, Pradaxa, and the newly-marketed Savaysa are all members of a class of drugs known as New Oral Anticoagulants (NOACs). They are all advertised as a safer and easier to use alternative to Warfarin (Coumadin), which has been the long-standing drug prescribed to patients who suffer from an irregular…